Humacyte, Inc. (HUMA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.60+1.49%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · HUMA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue commercial launch of Symvess and file supplemental BLA for ATEV in dialysis access in second half of 2026.
Stated as a priority in 3 recent quarters including 2026-Q2. Symvess commercial sales increased from $0.1 million in 2025-Q2 to $0.4 million in 2026-Q2. Management plans to file a supplemental Biologics License Application for ATEV in dialysis access in the second half of 2026. The trajectory shows delivering progress in commercialization and regulatory filings.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Plan to file a supplemental Biologics License Application with the FDA during the second half of 2026.”
“Symvess commercial sales were $0.4 million in Q2 2026 compared to $0.1 million in Q2 2025.”
“Commercial launch of Symvess ongoing with plans for regulatory filings.”
Develop partnerships including nephrologist advisors and collaborations to support commercialization and market access.
Stated as a priority in 2 recent quarters including 2026-Q2. Management appointed key nephrologists as advisors and held KOL events to support commercialization and market access. These actions indicate ongoing efforts to expand strategic partnerships and collaborations, with limited direct financial metrics but clear operational delivery.
“Appointed key nephrologists as advisors to prepare for planned commercialization of ATEV in dialysis access.”
“Held virtual KOL event highlighting need for ATEV in AV access.”
Respond to Nasdaq notices regarding bid price below $1.00 and maintain listing compliance.
Stated as a priority in 2 quarters including 2026-Q2 and 2026-Q3. The company received Nasdaq notices in May and July 2026 regarding bid price below $1.00 per share for continued listing. This regulatory challenge remains unresolved as of the latest disclosures, indicating ongoing compliance efforts but no resolution yet.
“Received Nasdaq notice for bid price below $1.00 for 30 consecutive business days ended July 30, 2026.”
“Received Nasdaq notice for bid price below $1.00 for 30 consecutive business days ended May 1, 2026.”
Raise capital via public offerings to fund commercialization, regulatory filings, and pipeline development.
Stated as a priority in 2 quarters including 2026-Q1 and 2026-Q2. The company raised $57.5 million gross proceeds from a public offering in June 2026 to fund commercialization, regulatory filings, and pipeline development. This capital raise supports financial stability and aligns with management's stated priorities.
“Raised $57.5 million gross proceeds from public offering in June 2026.”
“Announced commencement of underwritten public offering of common stock.”
Reduce headcount by approximately 45 employees and achieve $14.3 million net savings in 2026.
Newly stated in 2026-Q2. Management implemented a workforce reduction of approximately 45 employees with estimated net savings of $14.3 million during 2026. This cost reduction initiative is recent and its full financial impact is yet to be reflected in operating expenses.
“Implemented workforce reduction of approximately 45 employees with estimated net savings of $14.3 million during 2026.”
Over the trailing year it converted 2.82x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates (low R² over the window).
18 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.